Garnier Anne, Bendall Jennifer K, Fuchs Sebastien, Escoubet Brigitte, Rochais Francesca, Hoerter Jacqueline, Nehme Johnny, Ambroisine Marie-Lory, De Angelis Noeleen, Morineau Gilles, d'Estienne Pauline, Fischmeister Rodolphe, Heymes Christophe, Pinet Florence, Delcayre Claude
INSERM U572, Université Paris 7, France.
Circulation. 2004 Sep 28;110(13):1819-25. doi: 10.1161/01.CIR.0000142858.44680.27. Epub 2004 Sep 13.
Elevated circulating aldosterone level is associated with impaired cardiovascular function. Although the mechanisms are not fully understood, aldosterone antagonists decrease total and cardiovascular mortality in heart failure and myocardial infarction. Aldosterone induces cardiac fibrosis in experimental models, and it is synthesized locally in rat heart. These observations suggest pathological effects of aldosterone in heart that remain unclear.
Transgenic mice (TG) that overexpress the terminal enzyme of aldosterone biosynthesis, aldosterone synthase (AS), in heart have been raised by gene targeting with the alpha-myosin heavy chain promoter. AS mRNA increased 100-fold and aldosterone concentration 1.7-fold in hearts of male TG mice relative to wild-type. No structural or myocardial alterations were evidenced, because ventricle/body weight, AT1 and AT2 receptor binding, and collagen content were unchanged in TG. No alteration in cardiac function was evidenced by echocardiography, isolated perfused heart, or whole-cell patch clamp experiments. In contrast, coronary function was impaired, because basal coronary flow was decreased in isolated perfused heart (-55% of baseline values), and vasodilatation to acetylcholine, bradykinin, and sodium nitroprusside was decreased by 75%, 60%, and 75%, respectively, in TG mice compared with wild-type, showing that the defect was not related to NO production.
Increased cardiac aldosterone production in male mice induces a major coronary endothelium-independent dysfunction with no detectable alterations in cardiac structure and function. However, coronary dysfunction may be harmful for coronary adaptation to increased flow demand.
循环中醛固酮水平升高与心血管功能受损有关。尽管其机制尚未完全明确,但醛固酮拮抗剂可降低心力衰竭和心肌梗死患者的总死亡率及心血管死亡率。醛固酮在实验模型中可诱导心脏纤维化,且在大鼠心脏中可局部合成。这些观察结果提示醛固酮在心脏中的病理作用仍不明确。
通过以α-肌球蛋白重链启动子进行基因靶向,培育出在心脏中过表达醛固酮生物合成末端酶醛固酮合酶(AS)的转基因小鼠(TG)。相对于野生型雄性TG小鼠,心脏中AS mRNA增加了100倍,醛固酮浓度增加了1.7倍。由于TG小鼠的心室/体重、AT1和AT2受体结合以及胶原蛋白含量均未改变,因此未发现结构或心肌改变。超声心动图、离体灌注心脏或全细胞膜片钳实验均未证明心脏功能有改变。相比之下,冠状动脉功能受损,因为在离体灌注心脏中基础冠状动脉血流量减少(为基线值的-55%),与野生型相比,TG小鼠对乙酰胆碱、缓激肽和硝普钠的血管舒张分别降低了75%、60%和75%,表明该缺陷与一氧化氮生成无关。
雄性小鼠心脏中醛固酮生成增加会导致主要的冠状动脉非内皮依赖性功能障碍,而心脏结构和功能未检测到改变。然而,冠状动脉功能障碍可能对冠状动脉适应增加的血流需求有害。